Skip to content

Study · Non-randomized trial · 2006

7 results

[Clastogenic, aneugenic, pro- and antioxidant properties of some neurotropic preparations].

Gaĭtetdinova DD, Semenov VV, Ismagilov MF, Kharitonov VS

Eksperimental'naia i klinicheskaia farmakologiia1 May 2006Cited by 1 (Europe PMC)

PMID16878503 (opens in a new tab)PepBankPUB-16878503
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialMechanism

    In patients with infantile cerebral palsy, Cerebrolysin reduced aneugenesis and clastogenesis more than encephabol.

    In plain wordsIn patients with cerebral palsy, Cerebrolysin reduced chromosome damage more than encephabol.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseAneugenesis and clastogenesis (erythrocyte micronuclei)
    Study

    n: not reported in source

    Comparator
    Encephabol
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The modifying effect of preparations was not univalent: it was cerebrolysin that decreased intensivity of aneu- and clastogenesis in patients in a greater degree than encephabol.
    1 context sentence
    Summary · context
    The ability of such preparations as ceredrolysin and encephabol to decrease erythrocyte high level with micronuclei in peripheric blood of patients with infantile cerebral palsy (spastic diplegia) was clinically investigated.
  2. 02LabOther designMechanism

    In chemical, fermentative and cellular models, Cerebrolysin inhibited superoxide anion-radical generation.

    In plain wordsIn lab tests, Cerebrolysin reduced superoxide generation.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSuperoxide generation
    Study

    n: not reported in source

    Chemical, fermentative and cellular model systems
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In chemical, fermentative and cellular model systems, cerebrolysin inhibited generation of superoxide anion-radical, nitrogen monoxide and final products of degradation of fatty acids.
  3. 03LabOther designMechanism

    In chemical, fermentative and cellular models, Cerebrolysin inhibited nitrogen monoxide generation.

    In plain wordsIn lab tests, Cerebrolysin reduced nitrogen monoxide generation.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNitrogen monoxide generation
    Study

    n: not reported in source

    Chemical, fermentative and cellular model systems
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In chemical, fermentative and cellular model systems, cerebrolysin inhibited generation of superoxide anion-radical, nitrogen monoxide and final products of degradation of fatty acids.
  4. 04LabOther designMechanism

    In chemical, fermentative and cellular models, Cerebrolysin inhibited generation of final fatty-acid degradation products.

    In plain wordsIn lab tests, Cerebrolysin reduced fatty-acid degradation products.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseFatty-acid degradation products
    Study

    n: not reported in source

    Chemical, fermentative and cellular model systems
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In chemical, fermentative and cellular model systems, cerebrolysin inhibited generation of superoxide anion-radical, nitrogen monoxide and final products of degradation of fatty acids.
  5. 05LabOther designMechanism

    In C. capillaries experiments, Cerebrolysin showed the most pronounced anticlastogenic activity among the tested preparations.

    In plain wordsIn lab tests with C. capillaries, Cerebrolysin showed the strongest protection against chromosome breakage among tested preparations.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseAnticlastogenic activity
    Study

    C. capillariesn: not reported in source

    C. capillaries experiments
    Comparator
    Other tested neurotropic preparations
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The most pronounced anticlastogenic activity during expriments on C. capillaries had a cerebrolysin.
    1 context sentence
    Summary · context
    In experimental and clinical investigations, assessment was made of mutagenous, antimutagenous, pro- and antiradical activity of some neurotropic preparations--cerebrolysin, encephabol (pyritinol), nootropil (piracetam), actovegin and cavinton (vinpocetine).

Studies that did not test the peptide alone2

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 06HumanNot a test of Cerebrolysin aloneNon-randomized trialMechanism

    In boys with infantile cerebral palsy, protection with the tested preparations, including Cerebrolysin and encephabol, was pronounced on the 10th day.

    In plain wordsIn boys with cerebral palsy, protection with the tested preparations, including Cerebrolysin and encephabol, was pronounced on the 10th day.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableProtective effect timing in boys
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    Time when protective effect was pronounced
    10 day
    boys with infantile cerebral palsy, tested preparations including Cerebrolysin and encephabol

    Source sentences

    Summary
    A protective effect of these preparations was pronounced on the 10th day in group of the boys, and on the 20th day in the group of the girls.
    1 context sentence
    Summary · context
    The ability of such preparations as ceredrolysin and encephabol to decrease erythrocyte high level with micronuclei in peripheric blood of patients with infantile cerebral palsy (spastic diplegia) was clinically investigated.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 07HumanNot a test of Cerebrolysin aloneNon-randomized trialMechanism

    In girls with infantile cerebral palsy, protection with the tested preparations, including Cerebrolysin and encephabol, was pronounced on the 20th day.

    In plain wordsIn girls with cerebral palsy, protection with the tested preparations, including Cerebrolysin and encephabol, was pronounced on the 20th day.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableProtective effect timing in girls
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    Time of pronounced protective effect
    20 day
    Girls with infantile cerebral palsy, tested preparations including cerebrolysin and encephabol

    Source sentences

    Summary
    A protective effect of these preparations was pronounced on the 10th day in group of the boys, and on the 20th day in the group of the girls.
    1 context sentence
    Summary · context
    The ability of such preparations as ceredrolysin and encephabol to decrease erythrocyte high level with micronuclei in peripheric blood of patients with infantile cerebral palsy (spastic diplegia) was clinically investigated.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.